NCT03835819 2025-05-15A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)Dana-Farber Cancer InstitutePhase 2 Active not recruiting18 enrolled 17 charts
NCT03106077 2020-12-02Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast CancerM.D. Anderson Cancer CenterPhase 2 Completed96 enrolled 8 charts